TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04248894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training of High Intensity
Description: High intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training of Moderate Intensity
Description: Moderate intensity

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Untraining
Description: Sedentary
Study: NCT00308074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: open-label, flexible-dosing
Study: NCT02986932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBB opening
Description: Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
Study: NCT03922165

Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: Routine AT per clinical care.
Study: NCT03644082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Memory Matrix
Description: The purpose id to remember the location of squares on a grid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Famliar Faces
Description: The purpose is to create associations between visual and verbal information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Brain Shift
Description: The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Star Search
Description: The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Word Bubbles
Description: The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Color Match
Description: The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
Study: NCT02036762

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching Exercises
Description: The group submitted to stretching exercises in the respiratory muscles and treadmill exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercises
Description: The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
Study: NCT01035346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of a placebo
Study: NCT02728804

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT00484939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
Study: NCT00050674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim-SD/01
Description: 6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
Study: NCT04056780

Intervention type: OTHER
Intervention: Sample collection study
Description: Sample collection and collection of laboratory values

Intervention type: OTHER
Intervention: Sample collection study
Description: Sample collection and collection of laboratory values
Study: NCT00740623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: 800 mg/day for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: 1,200 mg/day for 14 weeks
Study: NCT03968523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Novel local infiltration technique
Description: Local analgesic infiltration in the mesh fixation site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: TAP block technique
Study: NCT02223533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19Gx500-mm Pajunk InfiltraLong® catheter
Description: Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
Study: NCT03644082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Ebb and Flow
Description: Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
Study: NCT02223533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
Study: NCT03883113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Trial Vaccine
Study: NCT00484939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
Study: NCT03936868

Intervention type: PROCEDURE
Intervention: Tendon transfer
Description: flexor carpi radialis transfer in most of patients and boye-transfer in very few
Study: NCT00750867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin (IVIg)
Description: The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
Study: NCT03088345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine
Description: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
Study: NCT03955731

Intervention type: DEVICE
Group type: OTHER
Intervention: Magmaris resorbable magnesium scaffold
Description: Implantation of Magmaris resorbable magnesium scaffold
Study: NCT03646955

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No partial breast irradiation
Description: Omission of radiation therapy
Study: NCT03644082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity TrialChalk Board Challenge
Description: purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
Study: NCT03883113

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium Chloride Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2 (A/Belgium/2417/2015)
Description: Challenge Agent
Study: NCT00495274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
Study: NCT03883113

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H3N2 (A/Belgium/2417/2015)
Description: Challenge Agent
Study: NCT02677844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT00495274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G
Description: Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
Study: NCT03202641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP ARDSnet
Description: PEEP settings based on the low PEEP/high FiO2 table

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP LRM
Description: A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
Study: NCT01032057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Study: NCT02677844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally
Study: NCT01032057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT02677844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: Administered orally
Study: NCT01032057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Study: NCT04187183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Platelet Rich Plasma with leukocyte
Description: autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Platelet Rich Plasma without leukocyte
Description: autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint
Study: NCT03111810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4017 and prednisolone
Description: The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet and prednisolone
Description: Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
Study: NCT00422955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Study: NCT01854918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
Study: NCT02083887

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP / MVA ME-TRAP
Description: Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
Study: NCT01854918

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Study: NCT00354627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC125
Description: 200 mg b.i.d. till commercially available.
Study: NCT00788801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
Study: NCT02840760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stimulate the primary motor cortex for 2 weeks.
Study: NCT02652286

Intervention type: DEVICE
Group type: OTHER
Intervention: HARMONIC ACE+7
Description: Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
Study: NCT04569890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol 200 MG/ML [Cimzia]
Description: CZP 200mg twice a week subcutaneous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400mg HCQ orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 10mg GC orally daily
Study: NCT02083887

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP / MVA ME-TRAP
Description: Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP / MVA ME-TRAP
Description: Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
Study: NCT01305655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Patients treated with Glucarpidase if the 24 hour levels of MTX is \>250 µM, 36 hour levels \>30 µM or 42 hours levels \>10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
Study: NCT03434314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-Invasive Segmental Artery Coil-Embolization
Description: During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
Study: NCT00053482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM2000 Smallpox Vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM2000 Smallpox Vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM2000 Smallpox Vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM2000 Smallpox Vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
Description: Group 5 dose: 1.0x10-8th PFU/ml
Study: NCT01682694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine and Chondroitin
Description: Glucosamine (1500 mg) and Chondroitin (1200 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03091569

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K Cream
Description: To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
Study: NCT03829345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
Study: NCT00096018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Orally
Study: NCT02949388

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg (200 mg BID)
Description: Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg (150 mg BID)
Description: Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
Study: NCT00921310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study: NCT01221194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Stockings
Description: A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
Study: NCT03644082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosiuty Follow that Frog
Description: The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Train of Thought
Description: purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
Study: NCT04577326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
Study: NCT00369486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg triamcinolone
Description: Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg triamcinolone
Description: Anterior peribulbar injection of 20 mg triamcinolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg triamcinolone + laser
Description: Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg triamcinolone + laser
Description: Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
Study: NCT02439970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Study: NCT01117935

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated external beam radiation therapy
Description: Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes